

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

APPOINTMENT OF CHAIRMAN, VICE CHAIRMAN AND CHIEF SUPERVISOR

麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the first meeting of the 11th session of the board of directors of the Company appointed Mr. Zhu Baoguo as the chairman (the “**Chairman**”) of the 11th session of the board of directors of the Company, and appointed Mr. Tao Desheng and Mr. Xu Guoxiang as the vice chairman (the “**Vice Chairman**”) of the 11th session of the board of directors of the Company on 30 June 2023. During their terms of office, Mr. Zhu Baoguo will be offered an annual director’s fee for the Chairman of RMB3,250,000 (before tax), and Mr. Tao Desheng and Mr. Xu Guoxiang will be both offered an annual director’s fee for the Vice Chairman of RMB3,000,000 (before tax). Mr. Xu Guoxiang is also entitled to an annual salary of RMB1,000,000 (before tax), plus discretionary bonus during his tenure which are determined by reference to his duties and responsibilities within the Company, the Company’s remuneration policy and the market salary range of the position.

On 30 June 2023, the first meeting of the 11th session of the supervisory committee of the Company appointed Mr. Wang Maolin as the chief supervisor (the “**Chief Supervisor**”) of the 11th session of the supervisory committee of the Company. During his term of office, Mr. Wang Maolin will be offered an annual supervisor’s fee for the Chief Supervisor of RMB72,000 (before tax) plus a salary and a bonus which are determined by reference to his duties and responsibilities within the Company, the Company’s remuneration policy and the market salary range of the position.

The tenures of the Chairman, Vice Chairmen and Chief Supervisor will commence on 30 June 2023, and end upon the expiry of the three-year tenure of the 11th session of the board of directors and the 11th session of the supervisory committee.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China

30 June 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*